Angiotensin II receptor inhibition a new therapeutic principle

Archives of Internal Medicine

Volumn 156, Issue 17, 1996, Pages 1957-1965

  Messerli, Franz H ^a,d   Weber, Michael A ^b   Brunner, Hans R ^c  

^a OCHSNER MEDICAL CENTER   (United States)

^b VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d OCHSNER CLINIC FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BRADYKININ RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN POTASSIUM; PLACEBO;

ANGIONEUROTIC EDEMA; CLINICAL FEATURE; CLINICAL TRIAL; COUGHING; DOSE RESPONSE; DRUG EFFICACY; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RECEPTOR BINDING; REVIEW; TREATMENT PLANNING;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; IMIDAZOLES; LOSARTAN; RECEPTORS, ANGIOTENSIN; TETRAZOLES;

EID: 0029797588     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.156.17.1957     Document Type: Review

References (100)

1. Materson BJ, Preston RA. Angiotensin-converting enzyme inhibitors in hypertension: a dozen years of experience. Arch Intern Med. 1994;154:513-523.
2. Groden DL. Vasodilator therapy for congestive heart failure: lessons from mortality trials. Arch Intern Med. 1993;153:445-454.
3. Cody RJ. Comparing angiotensin-converting enzyme inhibitor trial results in patients with acute myocardial infarction. Arch Intern Med. 1994; 154:2029-2036.
4. Hollenberg NK, Raij L. Angiotensin-converting enzyme inhibitors and renal protection: an assessment of implications for therapy. Arch Intern Med. 1993;153:2426-2435.
5. Chu TJ, Chow N. Adverse effects of ACE inhibitors. Ann Intern Med. 1993;118:314.
6. Israili ZH, Hall WD. Cough and angíoneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann Intern Med. 1992;117:234-242.
7. Smith RD, Chiu AT, Wong PC, Herblin WF, Timmermans PBMWM. Pharmacology of nonpeptide angiotensin II receptor antagonists. Annu Rev Pharmacol Toxicol. 1992;32:135-165.
8. Timmermans PBMWM, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993;45: 205-251.
9. Streeten DH, Andersen GH Jr, Dalakos TH. Angiotensin blockade: its clinical significance. Am J Med. 1976;60:817-824.
10. Brunner HR, Gavras H, Laragh JH. Specific inhibition of the renin-angiotensin system: a key to understanding blood pressure regulation. Prog Cardiovasc Dis. 1974;17:87-98.
11. Furukawa Y, Kishimoto S, Hishikawa K, inventors. Takeda Chemical Industries Ltd, assignee. Hypotensive imidazole-5-acetic acid derivatives. US patent 4 355 040. July 20, 1982.
12. Wexler RR, Carini DJ, Duncia JV, et al. Rationale for the chemical development of angiotensin II receptor antagonists. Am J Hypertens. 1992;5:209S-220S.
13. Wong PC, Price WA Jr, Chiu AT, et al. Nonpepide angiotensin II receptor antagonists: studies with EXP9270 and DuP 753. Hypertension. 1990;15:823-834.
14. Chiu AT, McCall DE, Price WA, et al. Nonpeptide angiotensin II receptor antagonists, VII: cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990;252:711-718.
15. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists, VIII: characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990; 252:719-725.
16. Wong PC, Price WA, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists, IX: antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990;252:726-732.
17. Wexler RR, Greenlee WJ, Irvin JD, et al. Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J Med Chem. 1996;39:625-656.
18. Bumpus FM, Catt KJ, Chiu AT, et al. Nomenclature for angiotensin receptors: a report of the Nomenclature Committee of the Council for High Blood Pressure Research. Hypertension. 1991;17:720-721.
19. Timmermans PBMWM, Chiu AT, Herblin WF, Wong PC, Smith RD. Angiotensin II receptor subtypes. Am J Hypertens. 1992;5:406-410.
20. Timmermans PBMWM, Benfield P, Chiu AT, Herblin WF, Wong PC, Smith RD. Angiotensin II receptors and functional correlates. Am J Hypertens. 1992;5:221S-235S.
21. Bernstein KE, Berk BC. The biology of angiotensin II receptors. Am J Kidney Dis. 1993;22: 745-754.
22. 1) receptor. Semin Nephrol. 1993;13:558-566.
23. Dzau VJ, Mukoyama M, Pratt RE. Molecular biology of angiotensin receptors: target for drug research? J Hypertens Suppl. 1994;12:S1-S5.
24. Munzenmaier DH, Greene AS. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. Hypertension. 1996; 27(pt 2):760-765.
25. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature. 1991;351:233-236.
26. Sasamura H, Hein L, Krieger JE, Pratt RE, Kobilka BK, Dzau VJ. Cloning, characterization, and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome. Biochem Biophys Res Commun. 1992;185:253-259.
27. de Gasparo M, Husain A, Alexander W, et al. Proposed update of angiotensin receptor nomenclature. Hypertension. 1995;25:924-927.
28. Christ DO, Kilkson T, Wong N, et al. Formation and disposition of EXP3174, a pharmacologically active metabolite of the novel angiotensin II receptor antagonist DuP 753. In: Program and abstracts of the International Society for the Study of Xenobiotica (ISSX); October 21-25, 1990; San Diego, Calif. Abstract 137.
29. Wong PC, Price WA Jr, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists, XI: pharmacology of EXP3174, an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990;255: 211-217.
30. Munafo A, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther. 1992;51:513-521.
31. Wong PC, Price WA Jr, Chiu AT, et al. Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats: nonpeptide angiotensin II receptor antagonists, X. Hypertension. 1990;15:459-468.
32. Bunkenburg B, Schnell C, Baum HP, Cumin F, Wood JM. Prolonged angiotensin II antagonism in spontaneously hypertensive rats: hemodynamic and biochemical consequences. Hypertension. 1991;18:278-288.
33. Inagami T, Murakami T, Higuchi K, Nakajo S. Roles of renal and vascular renin in spontaneous hypertension and switching of the mechanism upon nephrectomy: lack of hypotensive effects of inhibition of renin, converting enzyme, and angiotensin II receptor blocker after bilateral nephrectomy. Am J Hypertens. 1991; 4:15S-22S.
34. Brooks DP, Frederickson TA, Weinstock J, Ruffolo RR Jr, Edwards RM, Gellai M. Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs. Arch Pharmacol. 1992;345:673-678.
35. Tofovic SP, Pong AS, Jackson EK. Effects of angiotensin subtype 1 and subtype 2 receptor antagonists in normotensive versus hypertensive rats. Hypertension. 1991;18:774-782.
36. MacFadyen RJ, Tree M, Lever AF, Reid JL. Effects of the angiotensin II receptor antagonist losartan (DuP753/MK954) on arterial blood pressure, heart rate, plasma concentrations of angiotensin II and renin and the pressor response to infused angiotensin II in the salt-deplete dog. Clin Sci. 1992;83:549-556.
37. MacFadyen RJ, Tree M, Lever AF, Reid JL. Haemodynamic and hormonal responses to Losartan (DuP 753/MK 954) infusion during cardiac catheterization in conscious salt-deplete dogs. Clin Sci. 1993;85:157-163.
38. 1-receptor subtype. Br J Pharmacol. 1993; 110:761-771.
39. Cruickshank JM, Lewis J, Moore V, Dodd C. Reversibility of left ventricular hypertrophy by differing types of anti-hypertensive therapy. J Hum Hypertens. 1992;6:85-90.
40. Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a meta-analysis of 109 treatment studies. Am J Hypertens. 1992;5:95-110.
41. Dahlöf B, Hansson L. Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorothiazide. J Hypertens. 1992;10:1513-1524.
42. Mizuno K, Tani M, Hashimoto S, et al. Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats. Lite Sci. 1992;51:367-374.
43. Gohlke P, Linz W, Scholkens BA, et al. Angiotensin-converting enzyme inhibition improves cardiac function: role of bradykinin. Hypertension. 1994;23:411-418.
44. Bunkenburg B, van Amelsvoort T, Rogg H, Wood JM. Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension. 1992;20:746-754.
45. de Simone G, Devereux RB, Camargo MJF, Wallerson DC, Sealey JE, Laragh JH, Reduction of development of left ventricular hypertrophy in salt-loaded Dahl salt-sensitive rats by angiotensin II receptor inhibition. Am J Hypertens. 1996;9:216-222.
46. Martorana PA, Kettenbach B, Breipohl G, Linz W, Scholkens BA. Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist, Eur J Pharmacol. 1990;182:395-396.
47. Bao G, Gohlke P, Qadri F, Unger T. Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension. 1992; 20:74-79.
48. Gohlke P, Bunning P, Unger T. Distribution and metabolism of angiotensin I and II in the blood vessel wall. Hypertension. 1992;20:151-157.
49. Raya TE, Fonken SJ, Lee RW, et al. Hemodynamic effects of direct angiotensin II blockade compared to converting enzyme inhibition in rat model of heart failure. Am J Hypertens. 1991; 4(suppl):334S-340S.
50. Smits JFM, van Krimpen C, Schoemaker RG, Cleutjens JPM, Daemen MJAP. Angiotensin II receptor blockade after myocardial infarction in rats: effects on hemodynamics, myocardial DNA synthesis, and interstitial collagen content. J Cardiovasc Pharmacol. 1992;20:772-778.
51. Milavetz JJ, Raya TE, Johnson CS, Morkin E, Goldman S. Survival after myocardial infarction in rats: captopril versus losartan. J Am Coll Cardiol. 1996;27:714-719.
52. Fitzpatrick MA, Rademaker MT, Charles CJ, Yandle TG, Espiner EA, Ikram H. Angiotensin II receptor antagonism in ovine heart failure: acute hemodynamic, hormonal, and renal effects. Am J Physiol. 1992;263:H250-H256.
53. Husain A. The chymase-angiotensin system in humans. J Hypertens. 1993;11:1155-1159.
54. Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension. 1993;22:339-347.
55. Hagino T, Abe K, Tsunoda K, Yoshinaga K. Antihypertensive effect of a non-peptide angiotensin II receptor antagonist, MK954, in patients with essential hypertension [in Japanese]. Nippon Jinzo Gakkai Shi. 1992;34:133-140.
56. Tsunoda K, Abe K, Hagino T, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens. 1993;6:28-32.
57. Sweet CS, Nelson EB. How well have animal studies with losartan predicted responses in humans? J Hypertens. 1993;11:S63-S67.
58. Doig JK, McFadyen R, Sweet CS, Devlin AM, Reid JL. Haemodynamic and renal response to losartan during salt depletion or salt repletion. J Hypertens. 1993;11 (suppl 5):S419-S420. Abstract.
59. Bauer JH, Reams GP, Lau A. Effects of losartan on blood pressure, renin-aldosterone, and renal function in essential hypertension. J Am Soc Nephrol. 1993;4:529. Abstract.
60. Saine DR, Ahrens ER. Renal impairment associated with losartan. Ann Intern Med. 1996; 124:775.
61. Shaw W, Snavely D, Shahinfar S. Safety and efficacy of losartan (DuP 753, MK-954) in hypertensive patients with renal impairment. J Am Soc Nephrol. 1994;5:567. Abstract.
62. Gansevoort RT, de Zeeuw D, Shahinfar S, Red-field A, de Jong PE. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens Suppl. 1994; 12:S37-S42.
63. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int. 1994;45:861-867.
64. Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol. 1992;42:333-335.
65. Burnier MJ, Brunner HR. Angiotensin II receptor antagonists and the kidney. Opinion Nephrol Hypertens. 1994;3:537-545.
66. Sweet CS, Bradstreet DC, Berman RS, Jallard N, Saenz A, Weidler DJ. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens. 1994;7:1035-1040.
67. Ilson B, Boike S, Larouche J, Freed M, Jorkasky D. The angiotensin II receptor antagonist SB 03220 does not increase uric acid excretion in healthy men. J Am Soc Nephrol. 1994; 5:562-569.
68. Soffer BA, Wright JT Jr, Pratt JH, Wiens B, Goldberg AI, Sweet CS. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension. 1995;26:112-117.
69. Chobanian AV. Hypertension, growth factors, and their relevance to atherosclerotic vascular disease. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York, NY: Raven Press; 1995:1:515-521.
70. The Multicenter European Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation. 1992;86:100-110.
71. Prescott MF, Sawyer WK. ACE inhibition versus angiotensin II, AT, receptor antagonism: a review of effects on intimal lesion formation in animal model of vascular injury, restenosis, and atherosclerosis. Drug Dev Res. 1993;29:88-93.
72. 1 receptor antagonist: effects on smooth muscle cell migration and proliferation after balloon catheter injury. Am J Pathol. 1991;139: 1291-1296.
73. Janiak P, Pillon A, Prost J-F, Vilaine J-P. Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. Hypertension. 1992;20:737-745.
74. 2 receptor. Circulation. 1993;88: 1-469. Abstract.
75. Huckle WR, Drag MD, Acker WR, et al. Effects of subtype-selective and balanced angiotensin II receptor antagonists in a porcine coronary artery model of vascular restenosis. Circulation. 1996;93:1009-1019.
76. Pratt RE, Dzau VJ. Pharmacological strategies to prevent restenosis: lessons learned from blockade of the renin-antiotensin system. Circulation. 1996;93:848-852.
77. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers: inhibition of pressor response to exogenous angiotensin I and II. Circulation. 1991; 83:1333-1342.
78. Goldberg MR, Tanaka W, Barchowsky A, et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension. 1993;21:704-713.
79. Goldberg AI, Dunlay MC, Sweet CS. Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension. Am J Cardiol. 1995;75:793-795.
80. Grossman E, Peleg E, Carroll J, Shamiss A, Rosenthal T. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension. Am J Hypertens. 1994; 7:1041-1044.
81. Goldberg MR, Bradstreet TE, McWilliams EJ, et al. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension. 1995;25:37-46.
82. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol. 1993;35:290-297.
83. Gottlieb SS, Dickstein K, Fleck E, et al. Memonamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation. 1993;88: 1602-1609.
84. Doig JK, MacFadyen RJ, Sweet CS, Lees KR, Reid JL. Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/ MK954), in salt-deplete normal man. J Cardiovasc Pharmacol. 1993;21:732-738.
85. Gavras H, Brunner HR, Turini GA, et al. Anti-hypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med. 1978;298:991-995.
86. Mancia G, Parati G, Pomidossi G, et al. Modification of arterial baroreflexes by captopril in essential hypertension. Am J Cardiol. 1982;49: 1415-1419.
87. 1 receptor antagonist irbesartan in hypertension. Hypertension. 1995;25:22-29.
88. Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mildto-moderate hypertensive patients. J Cardiovasc Pharmacol. 1985;7(suppl 1):S52-S55.
89. Weidmann P, Boehlen LM, de Courten M, Ferrari P. Antihypertensive therapy in diabetic patients. J Hum Hypertens. 1992;6(suppl 2): S23-S36.
90. Moan A, Høieggen A, Nordby G, Eide IK, Kjeldsen SE. Effects of losartan on insulin sensitivity in severe hypertension: connections through sympathetic nervous system activity? J Hum Hypertens. 1995;9(suppl 5):S45-S50.
91. Nelson E, Arcuri K, Ikeda L, Snavely D, Sweet C. Efficacy and safety of losartan in patients with essential hypertension. Am J Hypertens. 1992; 5:19A. Abstract.
92. Weber MA, Byyny RL, Pratt H, et al. Blood pressure effects of the angiotensin II receptor blocker, losartan. Arch Intern Med. 1995;155:405-411.
93. Byyny RL. Losartan potassium lowers blood pressure measured by ambulatory blood pressure monitoring. J Hypertens. 1995;13(suppl 1):S29-S33.
94. Chan JCN, Critchley JAJH, Lappe JT, et al. A randomized, double-blind, parallel study of the antihypertensive efficacy and safety of losartan potassium compared to felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens. 1995;9:765-771.
95. Dunlay MC, Fitzpatrick V, Chrysant S, Francischetti EA, Goldberg AI, Sweet CS. Losartan potassium as initial therapy in patients with severe hypertension. J Hum Hypertens. 1995;9: 861-867.
96. Crazier I, Ikram H, Awan N, et al, for the Losartan Hemodynamic Study Group. Losartan in heart failure: hemodynamic effects and tolerability. Circulation. 1995;91:691-697.
97. Lang RM, Yellen LG, McKelvie RS, et al, on behalf of the Losartan Pilot Exercise Study Investigators. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. Circulation. 1994;90:I-602. Abstract.
98. Dickstein K, Chang P, Willenheimer R, et al. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol. 1995;26:438-445.
99. Lacourciere Y, Brunner H, Irwin R, et al, and the Losartan Cough Study Group. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens. 1994; 12:1387-1393.
100. Azizi M, Chatellier G, Guyene T-T, Murieta-Geoffroy D, Ménard J. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. Circulation. 1995;92:825-834.